Genmab A (GMAB) Net Cash Flow (2018 - 2026)
Genmab A's (GMAB) quarterly Net Cash Flow came in at -$183.0 million in Q1 2026, down 179.22% YoY from $231.0 million in Q1 2025, and down 148.93% on a QoQ basis from $374.0 million in Q3 2025.
Genmab A (GMAB) Net Cash Flow (2018 - 2026) Analysis & Trends
Genmab A (GMAB) has 8 years of Net Cash Flow data on file, last reported at -$183.0 million in Q1 2026.
- Quarterly Net Cash Flow fell 179.22% year-over-year to -$183.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $104.0 million (up 102.24% YoY) and the FY2025 annual result came in at $332.0 million, up 137.43% from the prior year.
- Net Cash Flow retreated to -$183.0 million in Q1 2026, from $374.0 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $374.0 million in Q3 2025 to a low of -$2.0 billion in Q4 2024.
- A 4-year average of -$542.3 million and a median of -$183.0 million in 2026 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2024 — Net Cash Flow tumbled 634.67% — and 2025, when it jumped 403.95%.
- Tracing GMAB's Net Cash Flow over 4 years: stood at -$274.0 million in 2023, then plunged by 634.67% to -$2.0 billion in 2024, then surged by 118.58% to $374.0 million in 2025, then sank by 148.93% to -$183.0 million in 2026.
- The last three Net Cash Flow figures came in at -$183.0 million (Q1 2026), $374.0 million (Q3 2025), and -$87.0 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Genmab A | 2.05 Bn | 548.77 Mn | 1.07 Bn | 241.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 241.00 Mn |
| Jun 30, 2026 | 241.00 Mn |
| Mar 31, 2026 | -183.00 Mn |
| Mar 31, 2026 | -183.00 Mn |
| Sep 30, 2025 | 374.00 Mn |
| Sep 30, 2025 | 374.00 Mn |
| Jun 30, 2025 | -87.00 Mn |
| Jun 30, 2025 | -87.00 Mn |
| Mar 31, 2025 | 231.00 Mn |
| Mar 31, 2025 | 231.00 Mn |
| Dec 31, 2024 | -2.01 Bn |
| Dec 31, 2024 | -2.01 Bn |
| Sep 30, 2024 | -1.29 Bn |
| Sep 30, 2024 | -1.29 Bn |
| Jun 30, 2024 | -1.57 Bn |
| Jun 30, 2024 | -1.57 Bn |
| Mar 31, 2024 | -76.00 Mn |
| Mar 31, 2024 | -76.00 Mn |
| Dec 31, 2023 | -274.00 Mn |
| Dec 31, 2023 | -274.00 Mn |